Cellectar Biosciences is progressing toward regulatory submissions for its lead radiotherapeutic drug candidate, iopofosine I 131, focusing on treatment of Waldenström's macroglobulinemia after prior therapies. The company recently received favorable yet non-binding scientific advice from the EMA regarding conditional marketing authorization in Europe and plans an FDA NDA submission targeting accelerated approval. However, liquidity remains tight with cash sufficient only to early-mid 2026, forcing a reliance on additional financing to sustain clinical development and regulatory efforts. Success depends highly on navigating regulatory discretion and securing further capital.